Biotech

stock market down market bear market benny
Biotech

Galectin's stock halves after phase 3 MASH trial misses goal

Since the biotech shared the phase 3 data this morning, the company’s stock has dropped 54%, from $2 per share to 92 cents.
Gabrielle Masson Dec 20, 2024 2:40pm
Person holding a sign saying Help from behind a stack of paperwork and boxes

Applied CEO steps down in wake of FDA rejection, warning letter

Dec 20, 2024 12:51pm
Hybrid FSPFSO Solutions Keep Biotech Trials on Time and on Budget

Hybrid FSP/FSO Solutions Keep Biotech Trials on Time and on Budget

Nov 1, 2024 8:00am
scoop of pink ice cream

Sanofi scoops up China rights to Cytokinetics’ heart disease med

Dec 20, 2024 11:07am
video
Carl Sailer on AI market trends and strategic planning in biotech

Carl Sailer on AI, market trends, and strategic planning in biotech

Oct 28, 2024 8:00pm
dart board miss failure

Apollomics, after giving up on leukemia drug, posts ph. 3 fail

Dec 20, 2024 9:30am